To Assess Safety, Tolerability and Physiological Effects on Structure and Function of AXA4010 in Subjects With Sickle Cell Disease

Exclusion Criteria

• •Ten (10) or more Vascular-Occlusive Crisis (VOC)s that required hospital or emergency room (ER) visits within the past 12 months
• •Any clinically significant changes abnormalities on the screening 12-lead ECG
• •Estimated glomerular filtration rate \<60mL/min/1.73m2 appropriately corrected
• •Hemoglobin (Hb) ≤6.0 g/dL at Screening
• •Subjects on chronic transfusion regimens, or who received a transfusion within the last 2 months prior to screening
• •Experienced VOC or any other sickle crises (eg acute chest syndrome, splenic sequestration, dactylitis, stroke) within the last 2 months prior to Screening
• •Current or history of significant alcohol consumption
• •Other poorly controlled medical conditions as judged by the Investigator
• •Known sensitivity and/or history of clinically significant food intolerance/allergies to proteins (including whey, soy, casein, amino acids, etc.)
• •Unable or unwilling to adhere to contraception requirements
• •Any contraindications to an MRI scan for Cohort 2 only
• •Any other condition that, in the opinion of the Investigator, renders the subject at risk for compliance, compromises the well-being of the subject, or hinders study completion